Eli Lilly Reports Strong Earnings Growth Driven by Weight Loss Drugs
Eli Lilly's stock rose this week after the company reported a 56% year-over-year revenue increase to $19.8 billion, driven by strong sales of its GLP-1 drugs Mounjaro and Zepbound. The company also raised its revenue and earnings targets, exceeding Wall Street's expectations.
Tickers: $LLY
Topics: Earnings Foundayo GLP-1 Drugs Mounjaro Revenue Growth Zepbound